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Abstract: Understanding of the functions of microRNAs in breast cancer and breast cancer stem cells have been a hope for the
development of new molecular targeted therapies. Here, it is aimed to investigate the differences in the expression levels of let-7a, miR10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in
MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel. MCF7s were obtained from parental MCF-7 cells. Cytotoxic activity of paclitaxel was determined by ATP assay. Total RNA isolation and
cDNA conversion were performed from the samples. Changes in expression levels of miRNAs were examined by RT-qPCR. Identified
target genes and proteins of miRNAs were analyzed with RT-qPCR and western blot analysis, respectively. miR-125b was significantly
expressed (2.0946-fold; p = 0.021) in MCF-7s cells compared to control after treatment with paclitaxel. Downregulation of SMO, STAT3,
NANOG, OCT4, SOX2, ERBB2 and ERBB3 and upregulation of TP53 genes were significant after 48 h treatment in MCF-7s cells.
Protein expressions of SOX2, OCT4, SMAD4, SOX2 and OCT4 also decreased. Paclitaxel induces miR-125b expression in MCF-7s cells.
Upregulation of miR-125b may be used as a biomarker for the prediction of response to paclitaxel treatment in breast cancer.
Keywords: Breast cancer, stem cells, MCF-7s, miR-125b, paclitaxel

1. Introduction
Breast cancer (BC) is the most common and deadly cancer
type among women in the world. Despite improvements
in BC therapy, local-regional recurrence and distant
metastasis still continues (Guo et al., 2019). Cancer
stem cells (CSCs) are shown as one of the main reasons
why today’s treatments are not provided with sufficient
effectiveness. CSCs are a small cell population that differs
from less tumorigenic cancer cells that make up the
overall tumor mass, with the ability to selfrenewal and
differentiation to many different cells (Mertins, 2014; Phi
et al., 2018). However, it is estimated that these cells are
not only responsible for the formation of new tumors but
also for the resistance to recurrence and chemotherapy
(Ari et al., 2013; Aztopal et al., 2018; Mertins, 2014; Phi et
al., 2018). Studies in recent years support this hypothesis
and reveal that there are many factors in inducing the
differentiation of CSCs (Aztopal et al., 2018; Mertins,
2014; Phi et al., 2018).

MicroRNAs (miRNAs) are small single-stranded RNA
molecules, approximately 18–24 nucleotides in length,
encoded from highly conserved DNA regions but not
translated into protein (Ling et al., 2013). These proteinencoding RNA molecules bind to target mRNAs that
are complementary to their nucleotide sequences and
perform posttranscriptional gene expression regulation
by translational suppression or mRNA degradation
(Flatmark et al., 2016). Thus, miRNAs are involved in
many metabolic pathways to provide hemostasis in the
cell. They are especially effective in processes such as
cell growth, differentiation, cell death mechanisms and
apoptosis. In many studies, it has been stated that miRNAs
affect metabolic processes in many cancers including BC
(Ling et al., 2013; Bertoli et al., 2016; Flatmark et al., 2016).
The effectiveness of cancer treatment is often limited
to acquired resistance to chemotherapy. Despite progress
in identifying molecular determinants of the cancer
chemotherapy response, a comprehensive understanding
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of the mechanisms underlying drug resistance is still a
challenge (Mansoori et al., 2017). Paclitaxel is a type of
taxane antimicrotubule drug. It usually acts on the G2-M
phase (inhibits mitosis) and leads to apoptotic cell death.
However, it controls intercellular signaling by regulating
gene expression levels. This compound is commonly
utilized in BC chemotherapy due to its unique role in
stabilizing microtubule polymerization and polymerized
microtubules. At the present time, although paclitaxel is
involved in first-line therapy, the molecular mechanisms of
paclitaxel therapy are still unknown (N. Chen et al., 2014;
Samli et al., 2019). Recently, changes in miRNA expression
profiles have revealed that BC is highly associated with
function of CSCs and cancer therapy resistance (Mansoori
et al., 2017; Loh et al., 2019). To date, studies on miRNA
expression alterations in BC have been widely performed
in cell lines and clinical samples, but the number of studies
performed in CSCs is very few (Bertoli et al., 2015; Prabhu
et al., 2020).
Therefore, our study aims to investigate differences
in expression levels on MCF-7 and MCF-7s cells of 10 of
miRNAs (let-7a, miR-10b, miR-21, miR-125b, miR-145,
miR-155, miR-200c, miR-221, miR-222 and miR-335) that
were previously shown to be related to BC prognosis, drug
response and CSC biology. We have found that miR-125b
seems to be a candidate biomarker that deserves further
attention.
2. Materials and methods
2.1. Cell lines and chemicals
BC cell line, MCF-7, was cultured in RPMI 1640 Medium
(Gibco, USA) supplemented with100 U/mL penicillin (+)
100 μg/mL streptomycin (Gibco, USA), 2 mML-glutamine
(Gibco, USA), and 5% fetal bovine serum (Gibco, USA),
at 37 °C in a humidified atmosphere containing 5% CO2.
Paclitaxel (2 mg/mL) was obtained from the pharmacy of
the Medical School of Bursa Uludağ University. Paclitaxel
was aliquoted and stored at room temperature and diluted
in culture medium.
2.2. Mammosphere (stem cell-enriched population)
culture from MCF-7 cell line
After centrifugation, the MCF-7 cell pellet was prepared
as a single cell suspension and seeded (2.5×105 cells/mL)
in 25 cm2 ultralow attachment cell culture flasks (Corning
Inc., Corning, NY) at 37 °C in a humidified atmosphere
containing 5% CO2. The protocol in the previous study
was followed for the mammosphere culture medium
(Aztopal et al., 2018). Mammosphere (stem cell-enriched
population) isolated by magnetic separation and then
measured CD44+/CD24- percentage, which breast
cancer stem cells marker by flow cytometry as given
Supplementary Figure. After the mammosphere structures
were formed (3–4 days), they were collected by 800G
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10 min centrifugation and mechanically-enzymatically
(Tryple Select; Gibco, USA) decomposed. Single cells were
then replated for subsequent passages.
2.3. The ATP viability assay
Depending on the luminescence-based methodology, the
ATP method can be performed much more sensitively
and reliably than other viability methods in terms of in
vitro cytotoxicity measurements. Cellular ATP is the
most sensitive endpoint for measuring cell viability. ATP
content that is perfectly correlated with viability, meaning
the less ATP, the less viability, even meaning no ATP,
no viability. The level of intracellular ATP content is an
indicator used to determine the number of living cells
(Andreotti et al., 1995; Dexter et al., 2003; Ulukaya et al.,
2008). ATP cell viability assay was carried out following
the manufacturer’s instructions (ATP Bioluminescent
Assay Kit, Sigma, Steinheim, Germany). MCF-7s cells
were seeded on 96-well ultralow attachment cell culture
plate in triplicates at a density of 5×103 cells per well and
treated with the drug. Paclitaxel (0.25–15.93 µM) was
applied at different concentrations. Cells were incubated
with the treatment groups for 24 and 48 h at 37 °C in a
5% CO2. After the treatment period, the ATP assay was
performed as previously depicted (Ulukaya et al., 2008).
2.4. RNA isolation from parental MCF-7 and MCF-7s
specimens
MCF-7 and MCF-7s cells were seeded at a density of 1×105
cells per well of a 6-well plate and cells were harvested
for RNA isolation 24 and 48h after the treatment with
paclitaxel (3.98 µM). RNA isolation was performed
accordance with the manufacturer’s instructions using
the total RNA purification kit (Thermo Fisher Scientific,
USA). RNA concentration was measured using NanoDrop
2000 (Thermo Fisher Scientific, USA).
2.5. Real-time quantitative PCR-based miRNA
expressions
The 10 most important miRNAs (Table 1) in BC
development (Calin et al., 2006; Iorio et al., 2008; Visone
et al., 2009; Erturk et al., 2014) were analyzed in MCF-7
and MCF-7s cells. cDNA synthesis was performed with
the SCRIPT cDNA synthesis kit (Thermo Fisher Scientific,
USA) using 500 ng of total RNA for each group according
to the manufacturer’s specifications. Then, MCF-7 and
MCF-7s cells were analyzed on an Applied Biosystems
Step One Plus Real-Time PCR (Thermo Fisher Scientific,
USA). Analyses were made in triplicate for each sample
and two independently experiment. To evaluate the
miRNA expression, RNU6 was used as reference gene. The
average Ct values of this housekeeping gene from this assay
was used as a baseline to normalize the miRNA expression
data and to increase the accuracy.
Relative expression was calculated using the
comparative Ct method. The fold change of miRNA
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Table 1. miRNAs in BC development.
Accesion ID

miRNA

Localization

MIMAT0000062

hsa-let-7a

22q13.31

Putative
Function
TS

MIMAT0000254

hsa-miR-10b

2q31.1

O

MIMAT0000076

hsa-miR-21

17q23.2

O

MIMAT0000423

hsa-miR-125b 11q24.1

TS

MIMAT0000437

hsa-miR-145

5q32

TS

MIMAT0000646

hsa-miR-155

21p21.3

O

MIMAT0000617

hsa-miR-200c

12p13.31

TS

MIMAT0000278

hsa-miR-221

Xp11.3

O

MIMAT0000279

hsa-miR-222

Xp11.3

O

MIMAT0000765

hsa-miR-335

7q32.2

TS

TS: Tumor supressor, O: Oncogenic.

expressions was evaluated by the 2–ΔCt method (Livak et
al., 2001). A web-based software package was used for data
analysis (http://pcrdataanalysis.sabiosciences.com/mirna/
arrayanalysis.php).
2.6. Identification of differentially expressed miRNA
target genes
In order to identify miRNA target genes, miRBase
(http://www.mirbase.org) and Targetscan (http://www.
targetscan.org) were identified by scanning. Furthermore,
MiRTarBase and MiRDB were examined to evaluate the
target genes of statistically significant miRNA.
2.7. Evaluation of the expression level of miRNA target
genes
To determine the expression of the target genes of miR125b, RNAs were reverse transcribed using a cDNA
synthesis kit (Thermo Fisher Scientific, USA). Next,

expression changes of target genes were examined by
RT-PCR using the samples obtained (Table 2). The
expression level of the human glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) housekeeping gene was also
evaluated. Gene expression analyses were made in triplicate
for each sample and two independently experiment. The
initial copy number of the samples and the threshold cycle
(Ct) for mRNA expression were identified using the Step
One Plus Real-Time PCR (Applied Biosystems, Thermo
Fisher Scientific, USA). The 2−ΔCt method was also used in
calculations (Livak et al., 2001).
2.8. Western blotting
Western blot technique was conducted as described
previously (Akgun et al., 2019). The membranes were
probed sequentially with SMAD family member 4
(SMAD4) (#38454), sex determing region Y HMG-box
2 (SOX2) (#3579), octamer-binding transcription factor
(OCT4) (#2750), epidermal growth factor receptor (EGFR)
(#4267) and GAPDH (#2118) antibodies (Cell Signaling
Technology, MA, USA). Then, HRP-linked anti-rabbit IgG
antibodies (Cell Signaling Technologies, MA, USA) were
used. HRP bound to membranes were visualized with the
Fusion FX-7 chemiluminescence imaging system (Vilber
Lourmat, Torcy, France). The experiment was repeated
two independently experiment.
2.9. Statistical analysis
To examine the effect of miRNA expressions on MCF-7
and MCF-7s cells, a statistical analysis was performed.
RT2 Profiler PCR Array Data Analysis (http://www.
sabiosciences.com/pcr/arrayanalysis.php) Spss (v23) and
GraphPad Prism 8 (Demo Version; GraphPad, San Diego,
CA) were used to investigate whether miRNA expressions
were significant on MCF-7 and MCF-7s. The significance
was calculated using Independent Sample T Test and oneway analysis of variance (ANOVA). Confidence intervals

Table 2. Primer sets used for RT-qPCR.
Gene

Forward

Reverse

ERBB2

5’ ACC TGC TGA ACT GGT GTA TG 3’

5’ GAC TCT TGA CCA GCA CGT T 3’

ERBB3

5’ GAC ACA ATG CCG ACC TCT C 3’

5’ GTT GGG CAA TGG TAG AGT AGA G 3’

TP53

5’ TGG TTC TAT GAC TTT GCC TGA TAC 3’

5’ CAT TCA GCT CTC GGA ACA TCT C 3’

STAT3

5’ TAC AGT GAC AGC TTC CCA ATG 3’

5’ CAC CAA AGT GGC ATG TGA TTC 3’

SMO

5’ CAA GCT CGT GCT CTG GTC 3’

5’ ATT CTC ACA CTT GGG CAT GTA 3’

BCL2

5’ GTG GAT GAC TGA GTA CCT GAA C 3’

5’ GAG ACA GCC AGG AGA AAT CAA 3’

OCT4

5’ GGA GGA AGC TGA CAA CAA TGA 3’

5’ CTC TCA CTC GGT TCT CGA TAC T 3’

SOX2

5’ CAC CTA CAG CAT GTC CTA CTC 3’

5’ TGG GAG GAA GAG GTA ACC A 3’

NANOG 5’ TCC TGA ACC TCA GCT ACA AAC 3’

5’ GCG TCA CAC CAT TGC TAT TC 3’

PARP

5’ CAA AGT CAC CCA GAG TCT TCT C 3’

5’ TGA CCA GCA GAA AGT CAA GAA 3’

GAPDH 5’ AAC AGC CTC AAG ATC ATC AGC 3’

5’ GCG TCA AAG GTG GAG GAG TG 3’
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of 95% were calculated using the associated estimated
standard errors. A value of p < 0.05, p < 0.01, and p < 0.001
was considered statistically significant.

4.9819-fold) and 6 miRNAs (miR-21, miR-125b, miR145, miR-155, miR-200c and miR-222), (1.057- to 13.737fold) were upregulated in MCF-7 cells (for 24 and 48 h,
respectively). Among the miRNAs that upregulated in
48 h, the expression of let-7a was 2.835-fold (p = 0.010)
and miR-21 was 2.5315-fold (p = 0.000096) remarkable
upregulated (24 and 48 h, respectively), (Table 4).
On the other hand, 6 miRNAs (miR-21, miR125b, miR-155, miR-200c, miR-222 and miR-335)
were downregulated 1.0093- to 28.443-fold and 4
miRNAs (let-7a, miR-10b, miR-145 and miR-221) were
upregulated 1.0918- to 1.6283-fold in MCF-7s for 24 h.
However, 3 miRNAs (let-7a, miR-155 and miR-221) were
downregulated 1.1225- to 3.1456-fold and 7 miRNAs
(miR-10b, miR-21, miR-125b, miR-145, miR-200c, miR222 and miR-335) were upregulated 1.5511-to 27.0958fold in MCF-7s for 48 h. Among these miRNAs, miR125b was 2.094-fold significantly upregulated in MCF-7s
compare to control group after 48 h treatment (p = 0.021),
(Table 5). There was no change in miR-125b expression
after 24 h of treatment.
3.3. Effects of paclitaxel treatment on target genes of
miR-125b in MCF-7s
Upregulation of miR-125b was found statistically
significant after 48 h of treatment in MCF-7s cells. For
this reason, miR-125b was targeted in gene and protein
analyzes. The target genes of miR-125b were determined
by searching from the literature and online databases.
Expression levels of these genes were evaluated by RTqPCR (Banzhaf-Strathmann et al., 2014; Y. Wang et al.,
2020). Among these selected genes OCT4, SOX2, Nanog
Homeobox (NANOG), signal transducer and activator
of transcription 3 (STAT3) and smoothened (SMO) are

3. Results
3.1. Cytotoxicity of paclitaxel on MCF-7s (stem cellenriched population)
ATP viability assay was used to evaluate the cytotoxic
effect of paclitaxel treatment in both MCF-7 and MCF7s. Different concentrations of paclitaxel (0.25–15.93 µM)
were used for 24 and 48 h (Figure 1). In MCF-7 and MCF7s cells, paclitaxel treatment was determined to decrease
cell viability depending on time and dose administered
(Figure 1, p < 0.01, p < 0.001). When MCF-7s cell viability
were evaluated, we observed that viability haven’t gone
below 50%. IC50 (concentration that kills 50% of cells)
values also support these results. This data shows that
MCF-7s cells are more resistant to paclitaxel treatment
compared to MCF-7 cells (Figure 1, Table 3). In addition,
in microscopic images, we observed that sphere structures
were disrupted after the addition of paclitaxel (Figure 2).
3.2. Evaluation of the miRNA expressions after paclitaxel
treatment in MCF-7s
An expression study of 10 miRNAs demonstrated that
some of the miRNAs were expressed at different levels
after treatment of paclitaxel (3.98 µM) compared with the
control cells. Results revealed that, miR-155 was 2.0186fold downregulated for 24 h and the expression of let-7a
was 2.8154-fold (p = 0.000041), miR-10b was 3.5227fold, miR-221 was 2.9828-fold and miR-335 was 3.1456fold downregulated in MCF-7 cells for 48 h. However, 9
miRNAs (let-7a, miR-10b, miR-21, miR-125b, miR-145,
miR-200c, miR-221, miR-222 and miR-335), (1.3629- to
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Figure 1. Viability of MCF-7 and MCF-7s cells after treatment with paclitaxel for 24 and 48 h measured by the ATP viability assay.
*Denotes statistically significant differences in comparison with control: *(p < 0.01); **(p < 0.001). Data are presented as mean ± SD (n
= 3).
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Table 3. IC50 values during 24 and 48
h of treatment according to the results
of ATP viability administered with
paclitaxel.
Cell Line

IC50 (24 h)

IC50 (48 h)

MCF-7

7.26 μM

<0.25 μM

MCF-7s

>15.93 μM

>15.93 μM

important in resistance to anti-cancer drugs, differentiation
and self-renewal of CSCs (Ben-Porath et al., 2008; Lengerke
et al., 2011; Zhao et al., 2011; Leis et al., 2012; Nagata et al.,
2014; Galoczova et al., 2018); tumor protein p53 (TP53)
and Poly (ADP-ribose) polymerase-1 (PARP) are effective
in repair mechanisms, apoptosis and CSC biology (Zeniou
et al., 2019; Uhlmann et al., 2020); B-Cell Leukemia/
Lymphoma 2 (BCL2) is involved in apoptosis processes and
CSC survival (Czerwinska et al., 2015) and finally Erb-B2
receptor tyrosine kinase 2 (ERBB2) and Erb-B3 receptor
tyrosine kinase 3 (ERBB3) are responsible for determining
the aggressive properties and drug resistance of BCs (J.
Chen et al., 2018). In general, these genes were selected
because they are associated with BC therapy resistance
and CSC biology. RT-qPCR analysis demonstrated that

expression levels of SMO, STAT3, NANOG, OCT4, SOX2,
ERBB2 and ERBB3 genes were decreased in MCF-7s cells
after 48 h treatment. In addition, TP53 gene expression
level was increased on MCF-7s cells in 48 h (Figure 3). The
differences in expression levels and the fold change values
are given in Table 6.
The reduction in expression levels of these genes (SMO,
STAT3, NANOG, OCT4 and SOX2) that are effective in
CSCs regulation has shown that paclitaxel suppresses the
stem cell properties of MCF-7s cells and the treatment is
effective. In addition, after 48 h of treatment, paclitaxel
has also been demonstrated to trigger downregulation
of ERBB2 and ERBB3, which are associated with poor
prognosis. Another finding that supports the efficacy of
the treatment is the triggering the induction of apoptosis
with an increase in TP53 expression level.
3.4. Effects of paclitaxel treatment on target proteins of
miR-125b in MCF-7s
To detect the protein expression levels of SMAD4, SOX2,
OCT4, and EGFR that were potential targets of miR-125b,
we also performed western blotting (Lengerke et al., 2011;
Zhao et al., 2011; Leis et al., 2012; Masuda et al., 2012;
Liu et al., 2014). Among these SMAD4 is a downstream
mediator of transforming growth factor beta (TGF-β)

CONTROL

PACLITAXEL
15.93 µM

7.97 µM

3.98 µM

Figure 2. The effects of paclitaxel treatment on mamosphere formation for 48 h. (X20).
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Table 4. Time dependent miRNA expressions in MCF-7 cells.
let-7a

miR-155

miR-10b

miR-221

miR-222

miR-335

miR-145

miR-200c

miR-21

miR-125b

0.05954

0.004688

0.014714

0.011385

0.056328

0.020617

0.770215

0.069992

1.494849

1.561934

Fold Change

2.835

0.4954

2.7511

4.9818

3.1675

3.6978

2.5609

1.3629

1.4845

2.1092

Fold Regulation

2.835

–2.0186

2.7511

4.9818

3.1675

3.6978

2.5609

1.3629

1.4845

2.1092

95% CI

(1.91–3.76)

(0.00001–1.09)

(0.00001–8.44)

(0.00001–13.41) (0.80–5.54)

(0.00001–8.93) (0.00001–5.58)

(0.20–2.52)

(0.80–2.17)

(0.00001–4.98)

*p value

0.010262

0.356686

0.394606

0.218809

0.060603

0.19278

0.205594

0.40021

0.18924

0.311871

0.037421

0.040107

0.002619

0.004304

0.023089

0.023303

0.95705

0.112656

1.81085

4.521078

Fold Change

0.3552

6.0349

0.2839

0.3353

4.1892

0.3179

13.737

1.5157

2.5315

1.057

Fold Regulation

–2.8154

6.0349

–3.5227

–2.9828

4.1892

–3.1456

13.737

1.5157

2.5315

1.057

95% CI

(0.31–0.40)

(0.00001–36.73) (0.00001–1.11)

(0.00001–0.88)

(0.00001–12.99) (0.00001–1.53) (0.00001–43.68) (0.14–2.89)

*p value

0.000041

0.370039

0.346856

0.306847

24 h 2^(-Avg.(Delta(Ct))

48 h 2^(–Avg.(Delta(Ct))

0.354623

0.818284

(0.30–1.82)

0.344629

0.000096

0.891101

miR-145

miR-200c

miR-21

*p values evaluated by independent sample T test with comparing control groups 2^(-Avg.(Delta(Ct)).

Table 5. Time dependent miRNA expressions in MCF-7s cells.

let-7a
24 h 2^(-Avg.(Delta(Ct)) 0.248273
Fold Change

miR-155

miR-10b

miR-221

miR-222

miR-335

miR-125b

0.011951

0.01019

0.064854

0.036314

0.010648

1.107009

0.002421

0.882703

2.265768

1.146

0.9117

1.107

1.6283

0.3711

0.1334

1.0918

0.0352

0.9908

0.1665

–1.0968

1.107

–7.4988

–1.0093

0.6071

Fold Regulation

1.146

1.6283

–2.6945

1.0918

–28.443

95% CI

(0.00001– 3.37) (0.00001– 6.39) (0.00001– 4.71)

(0.23– 3.03)

(0.00001– 1.41) (0.00001– 0.58)

(0.00– 2.18)

(0.00001– 0.20) (0.00001– 2.54) (0.03–0.30)

*p value

0.65884

0.420976

0.446397

0.642654

0.401774

48 h 2^(–Avg.(Delta(Ct)) 0.151075
Fold Change

0.378155

0.955554

0.345634

0.628202

0.36387

0.001532

0.028099

0.002416

0.041426

0.129408

0.705475

0.027268

1.04006

7.81728

0.8909

0.3798

4.8121

0.3179

1.6857

27.0958

10.2674

1.5511

3.1895

2.0946

–2.6329

4.8121

–3.1456

1.6857

27.0958

10.2674

1.5511

3.1895

2.0946
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Table 6. Fold change of genes that showed differences in expression.
Cell Line SMO
24 h
48 h
24 h
48 h

MCF–7
MCF-7s

BCL2

NANOG OCT4

2.21667 1.06333 –1.08773

1.12000

2.22000

–1.75519 2.14667 –1.35088 –1.75171

0.33101

–1.76012 –1.63528 –1.33587 –0.31186 –9.39394

–2.18496 2.43667 1.33333 –2.60860

0.49288 –3.10994 –2.90650 –1.03853 –3.22805 4.12000

1.60333

TP53

PARP

STAT3

SOX2

ERBB2

ERBB3

–1.91190 1.45000 –0.64461 3.05000

–4.16667 6.02667 –0.44856 –14.28571 –1.14284 –4.64905 –5.27290 –6.31410 –8.11966 –10.27778
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that regulates cell proliferation of CSCs, differentiation,
apoptosis and cancer progression (Liu et al., 2014). EGFR
(also known as ErbB1 and HER1), ERBB2 (HER2/neu and
HER2), ERBB3 (HER3), and ERBB4 (HER4), members of
the (EGFR)/(ERBB) family, are known among the most
important cancer molecular targets. EGFR overexpression
is related with therapy resistance, cell proliferation,
angiogenesis and CSCs enrichment in BC (Masuda et
al., 2012; Czerwinska et al., 2015; J. Chen et al., 2018). As
with gene selection, these proteins were also evaluated for
their suitability to our study and were preferred because
of their role in signal pathways, which are important in
BC development, drug resistance and stem cell regulation.
Western blot analysis of the present study indicated that
SMAD4, SOX2 and OCT4 protein expressions were
downregulated in paclitaxel treatment after 48 h (Figure
4).
This result showed that after 48 h treatment with
paclitaxel in MCF-7s cells caused a decrease in stem
cell markers (SMAD4, SOX2, and OCT4). However, the
expression of EGFR after 24 and 48 h of treatment did not
change significantly. In addition, there was no significant
change after 24 h treatment compared to control.
4. Discussion
The incidence of BC ranks first among women in the world
and second in overall rankings. It accounts for 25% of all
new cancer cases (Bray et al., 2018). Despite the decline
in mortality rates due to advances in early diagnosis and
treatment, BC is still responsible for the reason of death
in millions of women in the world. Although screening
methods are effective for the detection of BC at the
treatable stage, current methods are not sufficient for all
BCs (Erturk et al., 2014). For this reason, new prognostic
and diagnostic biomarkers are needed in BC to achieve
better disease outcome and prolong patient survival. As a
result of the determination that miRNAs act as regulators
of gene expression, these molecules have become both
possible therapeutic targets and identified as candidate
indicators for diagnosis and prognosis (Erturk et al., 2014;
Bertoli et al., 2015; Adhami et al., 2018).
In the current study, differences in the expression levels
of 10 miRNAs effective in BC prognosis (let-7a, miR-21,
miR-125b, miR-145, miR-155, miR-200c), drug response
(let-7a, miR-21, miR-125b, miR-221, miR-222) and CSC
biology (let-7a, miR-10b, miR-21, miR-125b, miR-155,
miR-221, miR-222, miR-335) were evaluated in the parental
MCF-7 and MCF-7 (stem cell-enriched population) after 24
and 48 h of treatment with paclitaxel. Our findings showed
that although there was no change in miR-125b expression
level after 24 h treatment, the expression level increased
2.091–fold after 48 h of paclitaxel treatment in MCF-7s
cells compared to control cells (p = 0.021). miR-125b is
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Figure 4. Protein expression changes in MCF-7s cells. MCF-7s
were treated with paclitaxel (3.98 µM) 24 and 48 h, SMAD4,
SOX2, OCT4 and EGFR protein expression changes quantified by
western blotting. Densitometry was performed with the ImageJ
software and densitometric analysis of the observed bands’
intensity normalized to GAPDH and quantified with respect
to controls set to 1.0. GAPDH, glyceraldehyde 3-phosphate
dehydrogenase. Data are presented as mean ± SD (n = 3).

related with invasion and metastasis, drug response and
stem cell regulation in different types of cancer, including
BC (Emmrich et al., 2014; Vilquin et al., 2015). Although
miR-125b plays an important regulatory role in BC, two
distinct roles of this miRNA have been reported (Nie et
al., 2019). Some studies demonstrated that breast tumor
tissues express low of miR-125b and that it plays a role
in tumor suppression (Banzhaf-Strathmann et al., 2014;
Vilquin et al., 2015; Y. Wang et al., 2020). However, other
researchers noticed that miR-125b overexpression in BC
cells stimulated paclitaxel resistance and high miR-125b
expression level was a biomarker for poor prognosis in
BC (Vilquin et al., 2015; Zhou et al., 2015). These different
results might be associated with tissue or cell specific
effects, recommending that different miRNA expression
in humans could detect functional specificity between
tissue and cell and might include complex gene regulation
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(Banzhaf-Strathmann et al., 2014; Nie et al., 2019; Y. Wang
et al., 2020). Our findings showed that miR-125b increased
2.094-fold after 48 h of treatment. This revealed that miR125b functions as a tumor suppressor and increases the
efficacy of paclitaxel treatment.
Chemotherapy resistance in BC is one of the main
obstacles for treatment and one of the distinguishing
features of BCSCs. Studies have revealed the potential role
of miR-125b on chemoresistance by regulating BCSC (N.
Chen et al., 2014; J. Chen et al., 2018; Y. Wang et al., 2020).
Wang et al. (2013) analyzed the function of miR‐125b in
BC stem cell‐like side population. And they found that
overexpression of miR‐125b correlated with an increase
in stem cell‐like tumor side population and CSC property.
Also, miR-125b showed positive correlation with paclitaxel
in chemoresistance (S. Wang et al., 2013). Furthermore,
Vilquin et al.’s (2015) in their work found that ectopic
overexpression of miR-125b or miR-205 and silencing of
miR-424 expression in sensitive MCF-7aro cells, play a
role in gaining resistance against letrozole and anastrozole.
They detected that upregulation of miR-125b expression
was associated with poor prognosis in BC (Vilquin et
al., 2015). Moreover, Kong et al. (2011) reported that the
upregulation of miR-125b in ovarian cancer is associated
with cisplatin resistance (Kong et al., 2011).
The roles of miR-125b have not been fully elucidated
in different tumor types, including breast tumors.
Although the studies in the literature emphasize that the
increase of miR-125b expression contributes to paclitaxel
resistance, in our study, the effectiveness of paclitaxel
treatment might be increased as a result of the increase
in miR-125b expression. In addition, the increase in miR125b expression supported paclitaxel therapy. This result
showed that the upregulation of miR-125b determined
tumor suppressive properties and, thus, increased the
effectiveness of paclitaxel treatment in this study. However,
if this level of regulation differs during carcinogenesis,
oncogenic or tumor suppressor pathways are activated or
blocked. Therefore, we think that increased or decreased
miR-125b expression in different tumors may contribute
to carcinogenesis (Banzhaf-Strathmann et al., 2014; Y.
Wang et al., 2020).
To understand the functional mechanism of miR-125b,
it is critical to identify targets involved in their regulation.
Through analysis using miRBase, TargetScan, MİRTarBase
and MİRDB, a number of important candidate targets for
miR-125b were predicted (Y. Wang et al., 2020). Among
these potential targets, downregulation of SMO, STAT3,
NANOG, OCT4, SOX2, ERBB2, ERBB3 and upregulation
of TP53 were significant in MCF-7s cells after 48 h treatment.
SOX2, OCT4, and NANOG are CSC markers associated
with tumor proliferation and tumor differentiation (BenPorath et al., 2008; Lengerke et al., 2011; Zhao et al., 2011;

Leis et al., 2012). In previous studies, in many carcinomas,
including BC, high expression of these genes has been
identified as a predictive biomarker for poor prognosis
(Ben-Porath et al., 2008; Kong et al., 2011; Czerwinska
et al., 2015). Also, it was determined that combinational
high expression of OCT4, SOX2, NANOG and other
transcription factors had roles in programming of somatic
cells into pluripotent stem cell-like cell types (Ben-Porath
et al., 2008; Lengerke et al., 2011; Zhao et al., 2011; Leis et
al., 2012). In addition, Ben-Porath et al. (2008) reported
in their study that SOX2, OCT4 and NANOG expressions
were high in BCSCs. In the current study, downregulation
of these CSC related markers after 48 h of treatment
showed that paclitaxel treatment is effective. It can be
thought that high miR-125b expression in MCF-7s cells
indirectly suppresses the expression of these markers by
supporting paclitaxel treatment. Besides other functions,
the expression level of STAT3, which is effective in terms of
its ability to promote cancer by regulating CSCs activities in
tumor biology, with SMO, which is one of the components
of the hedgehog (Hh) signaling pathway that plays a role
in embryonic development, were also determined in
low regulation (Galoczova et al., 2018). The reduction in
expression levels of these genes that are effective in CSCs
regulation has shown that after 48 h treatment, paclitaxel
suppresses the stem cell properties of MCF-7s cells, and
it was found to be successful for treatment. In addition,
after 48 h of treatment in MCF-7s cells, paclitaxel has also
been demonstrated to trigger downregulation of ERBB2
and ERBB3, which are associated with poor prognosis (
Masuda et al., 2012; J. Chen et al., 2018). Another finding
showing the effectiveness of treatment is the increased in
the expression level of TP53-induced apoptosis (Uhlmann
et al., 2020). Previous studies demonstrated that these
genes are essential for the regulator of cell proliferation and
maintenance of CSCs (Ben-Porath et al., 2008; Czerwinska
et al., 2015). Also, overexpression of these genes is
associated with cancer development and poor prognosis.
In the present study, the high expression level of miR-125b
mediates downregulation of these genes, suppressing the
efficacy of paclitaxel in MCF-7s cells after 48 h treatment.
For finding out the effect of miR-125b in protein
expression of its targets, four important targets, SMAD4,
SOX2, OCT4 and EGFR were selected from its validated
targets (Y. Wang et al., 2020). As reported above, SOX2
and OCT4 are stem cell predictor factors that induce the
expression of each other, regulate cancer progression,
and are biomarkers of CSCs (Ben-Porath et al., 2008). On
the other hand, serving as the central mediator of TGF-β
signaling pathway, SMAD4 is a potential prognostic
marker of breast carcinoma development, and it is critical
for stem cells’ self-renewal (Liu et al., 2014). Thus, it was
determined that the expression levels of CSCs markers
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decreased in both gene and protein analyzes. However,
other potential mechanisms still need to be explored to
develop new therapeutic methods.
5. Conclusion
In summary, it seems that miR-125b upregulation may
be a predictive biomarker for effect of paclitaxel on CSCs
of BC. In addition, paclitaxel has a satisfactory potential
to reduce the stemness property of cancer cells in BC.
Taken together, further research (e.g. animal models) are
warranted for proof-of-concept of the mechanism as well
as to develop miRNA-based treatment strategies in BCSCs.
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